middle.news
Starpharma Advances FDA Pathway and Expands Middle East Market with $20M Cash Buffer
10:16am on Wednesday 29th of January, 2025 AEDT
•
Biotechnology
Read Story
Starpharma Advances FDA Pathway and Expands Middle East Market with $20M Cash Buffer
10:16am on Wednesday 29th of January, 2025 AEDT
Key Points
Positive FDA feedback on DEP® SN38 clinical and regulatory pathway
Potential Fast Track designation and accelerated approval for DEP® SN38
Upcoming VivaGel® BV launches in Saudi Arabia and UAE
Improved Viraleze™ online sales following digital marketing efforts
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma (ASX:SPL)
OPEN ARTICLE